Abstracts tagged "Interleukins"

Abstract Number: 2539 • ACR Convergence 2023
Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA
Jinqi Liu¹, Yicong Li², Kai Fu¹, Chun Wu¹, Peter Schafer³, Sean Connolly¹, Ian M. Catlett⁴, Michael Maldonado¹, Robert Wong⁵, Paul Emery⁶, Yoshiya Tanaka⁷, Vivian Bykerk⁸, Clifton Bingham⁹, Thomas Huizinga¹⁰ and Roy Fleischmann¹¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Parexel International, Durham, NC, ³Bristol Myers Squibb, Belle Mead, NJ, ⁴Bristol Myers Squibb, Pennington, NJ, ⁵Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
Abstract Number: 0012 • ACR Convergence 2023
Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity
Órla Tynan¹, Achilleas Floudas², Nuno Neto³, Michael Monaghan³, Siobhán Wade⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Dublin City University, Dublin, Ireland, ³Department of Mechanical and Manufacturing Engineering, Trinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) encompass two of the most common forms of Inflammatory Arthritis. While common pathogenic mechanisms are involved in…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 2548 • ACR Convergence 2023
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Martin Rudwaleit¹, Matthew A. Brown², Floris Van Gaalen³, Nigil Haroon⁴, Lianne Gensler⁵, Carmen Fleurinck⁶, Alexander Marten⁷, Ute Massow⁸, Natasha De Peyrecave⁹, Thomas Vaux¹⁰, Katy White¹⁰, Atul Deodhar¹¹ and Irene van der Horst-Bruinsma¹², ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Genomics England, London, United Kingdom, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada, ⁵University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁶UCB Pharma, Oosterzele, Belgium, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ¹²Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands
Background/Purpose: Acute anterior uveitis ('uveitis'), or 'iritis', is a common extra-musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA).1 IL-17 has been implicated in the…
Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Lola Torz², Natalia Petersen², Ayal Ben-Zvi³ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Novo Nordic, Global Obesity Research, Malov, Denmark, ³Hebrew University of Jerusalem, Jerusalem, Israel
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
Abstract Number: 2569 • ACR Convergence 2023
Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
Sara Bindoli¹, Arianna De Matteis², STEPHANE MITROVIC³, Bruno Fautrel⁴, Loreto Carmona⁵, Fabrizio De Benedetti⁶ and On Behalf Of The Eular/PreS QoC011 Task Force Member⁷, ¹Rheumatology Unit, Dept of Medicine, University of Padova, Padova, Italy, ²IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ³Pitie Salpetriere Hospital, Sorbonne University, APHP, Paris, France, ⁴Sorbonne Université APHP, Paris, France, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ⁷EULAR/PReS QoC011 Task Force members are: Jordi Anton, Alexandre Belot, Claudia Bracaglia, Tamas Constantin, Lorenzo Dagna, Alessandro De Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei Grom, Yvan Jamilloux, Katarina Laskari, Calin Lazar, Francesca Minoia, Peter Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier-dit-Maire, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Bas Vastert, Tanita Wilhelmer, Carine Wouters., Paris, France
Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…
Abstract Number: 0090 • ACR Convergence 2023
Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis
Addison Pacheco¹, Michael Tang¹, Sinead Maguire², Melissa Lim¹, Fataneh Tavasolian³, Zoya Qaiyum⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
Abstract Number: 1747 • ACR Convergence 2023
A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells
Adela Navratilova¹, Klára Prajzlerová², Nora Růžičková³, Karel Pavelka⁴, Jiri Vencovsky⁵, Ladislav Senolt⁶, Maria Filkova³ and Lucie Andrés Cerezo³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
Abstract Number: 1782 • ACR Convergence 2023
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Catherine Manning¹, Nataliya Yeremenko², Jae-Hyuck Shim³, Daniel Montoro⁴, Dominique Baeten⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵UCB Pharma, Slough, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 0445 • ACR Convergence 2023
Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study
Anna Zubrzycka-Sienkiewicz¹, Maria Misterska-Skora², Małgorzata Socik Pojawa³, Kamilla Klama⁴, Martin Ullmann⁵, Corinne Petit-Frere⁵, Andras Illes⁵, Peter Baker⁵, Joëlle Monnet⁵ and Jan Brzezicki⁶, ¹Reumatika - Centrum Reumatologil, Warsaw, Poland, ²Centrum Medyczne Oporów, Wrocław, Poland, ³MICS Centrum Medyczne Warszawa, Warsaw, Poland, ⁴Solumed Centrum Medyczne, Poznań, Poland, ⁵Fresenius Kabi SwissBiosimilars, Eysins, Switzerland, ⁶Centrum Kliniczno Badawcze, Elbląg, Poland
Background/Purpose: Tocilizumab is an anti‑interleukin‑6 receptor monoclonal antibody indicated for treating rheumatoid arthritis (RA) and other inflammatory diseases. MSB11456 is a proposed biosimilar to US‑licensed…
Abstract Number: 1920 • ACR Convergence 2023
A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS005 in Patients with Moderate to Severe Psoriasis
Lin Cai¹, Zhanglei Mu², Xiaohua Tao³, Litao Zhang⁴, Chunlei Zhang⁵, Yumei Li⁶, Guoqiang Zhang⁷, Furen Zhang⁸, Xiuqin Dong⁹, Chengxin Li¹⁰, Aijun Chen¹¹, Zhuning Wu¹², Yuxian Zhu¹², Mengqi Zhang¹², Jiangnian Liu¹² and Jianzhong Zhang¹, ¹Peking University People’s Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Zhejiang Provincial People’s Hospital, Hangzhou, China, ⁴Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China, ⁵Peking University Third Hospital, Beijing, China, ⁶Affiliated Hospital of Jiangsu University, Suzhou, China, ⁷The First Hospital of Hebei Medical University, Shijiazhuang, China, ⁸Shandong Dermatology Hospital, Jinan, China, ⁹Guangdong Provincial People’s Hospital, Guangzhou, China, ¹⁰Chinese PLA General Hospital, Beijing, China, ¹¹The First Affiliated Hospital of Chongqing Medical University, Chongqing, China, ¹²Shanghai Junshi Biosciences, Shanghai, China
Background/Purpose: JS005 is a novel anti-IL-17A monoclonal antibody with unique patented complementarity-determining region (CDR) sequences. This Phase Ib/II study (NCT05344248) aimed to evaluate the safety,…
Abstract Number: 0779 • ACR Convergence 2023
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Laura PINA VEGAS¹, Laetitia Penso², Emilie Sbidian³ and pascal claudepierre⁴, ¹Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, ²Université Paris Est Créteil, Créteil, France, ³Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁴Universitary Henri Mondor Hospital, Creteil, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
Abstract Number: 2156 • ACR Convergence 2023
Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study
Vibeke Strand¹, Tatiana Lisitsyna², Anton Abramkin², Dmitry Veltishchev³, Olga Seravina³, Oksana Kovalevskaya³, Anastasia Borisova⁴, Sofia Kuzkina⁵, Vasily Ignatiev⁵ and EVGENY NASONOV⁶, ¹Stanford University, Portola Valley, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Moscow, Russia, ⁴Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Mosocw, Russia, ⁵R-Pharm, Moscow, Russia, ⁶Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Interleukin-6 (IL) plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors used to treat RA patients may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].